TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
November 11, 2014 11:31 AM ESTRoth Capital affirms TG Therapeutics (Nasdaq: TGTX) at Buy with a price target of $25 following Q3 results. TGTX posted Q3 loss of $0.51 per share, versus the firm's estimate looking for a loss of $0.32 per share.
Analyst Joseph Pantginis commented, Over the last 12 months, TG has transformed itself with what we consider to be striking clinical data to a pivotal stage company. The... More
TG Therapeutics (TGTX) Misses Q3 EPS by 19c
November 10, 2014 4:21 PM ESTTG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $38.1 million versus the consensus estimate of $30 thousand.
For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.
... More